Phosphate-binding capacity of ferrihydrite versus calcium acetate in rats

被引:15
作者
Weaver, CM [1 ]
Schulze, DG [1 ]
Peck, LW [1 ]
Magnusen, HM [1 ]
Martin, BR [1 ]
Gruenhagen, SE [1 ]
机构
[1] Purdue Univ, Dept Food & Nutr, W Lafayette, IN 47907 USA
关键词
phosphate binder; renal dialysis;
D O I
10.1016/S0272-6386(99)70362-8
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Calcium salts, such as calcium carbonate and calcium acetate, are the principal compounds used as phosphate binders in patients with chronic renal failure. The dose required is three to six times the normal requirement for calcium. Use of these large doses of calcium salts in the diet can result in hypercalcemia. Other compounds have been investigated as phosphate binders with varying degrees of success. Synthetic ferrihydrite (5Fe(2)O(3). 9H(2)O) has a high adsorptive capacity for phosphate and may be an effective phosphate binder. The phosphate-binding capacity of ferrihydrite was compared with that of calcium acetate in 250-g male Sprague Dawley rats. After an overnight fast, rats (n = 5 per group) were gavaged with an American Institute of Nutrition (AIN) 76 formula containing one third the daily phosphorus intake labeled with phosphorus-32 (P-32). Either two levels of calcium acetate, representing three (1/2 X) or six (1 X) times the usual calcium intake for one third of the day, or equivalent amounts of ferrihydrite were added to the diet. An additional group received two times (2 X) the larger dose, and a sixth control group received no binder in the diet. Phosphorus absorption curves were determined from P-32 appearance in the serum. The 1/2 X dose of ferrihydrite reduced P-32 by approximately one half, and the 2 X dose nearly completely suppressed P-32 absorption, similar to the 1 X dose of calcium acetate. The advantage of using a ferrihydrite binder would be to avoid the hypercalcemia resulting from the use of high-dose calcium salts. An added advantage may result from the small amounts of iron absorbed in these chronically iron-deficient patients. (C) 1999 by the National Kidney Foundation, Inc.
引用
收藏
页码:324 / 327
页数:4
相关论文
共 20 条
  • [1] *AM I NUTR, 1980, J NUTR, V110, P1426
  • [2] CLARKSON EM, 1972, CLIN SCI, V43, pL519
  • [3] DELMEZ JA, 1992, J AM SOC NEPHROL, V3, P96
  • [4] FOURNIER A, 1986, KIDNEY INT S18, V29, pS114
  • [5] HEM SL, 1990, Patent No. 4970079
  • [6] Llach F, 1998, AM J KIDNEY DIS, V32, pS3
  • [7] DEATH RISK IN HEMODIALYSIS-PATIENTS - THE PREDICTIVE VALUE OF COMMONLY MEASURED VARIABLES AND AN EVALUATION OF DEATH RATE DIFFERENCES BETWEEN FACILITIES
    LOWRIE, EG
    LEW, NL
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 1990, 15 (05) : 458 - 482
  • [8] MACTIER RA, 1987, CLIN NEPHROL, V28, P222
  • [9] CALCIUM ACETATE, AN EFFECTIVE PHOSPHORUS BINDER IN PATIENTS WITH RENAL-FAILURE
    MAI, ML
    EMMETT, M
    SHEIKH, MS
    SANTAANA, CA
    SCHILLER, L
    FORDTRAN, JS
    [J]. KIDNEY INTERNATIONAL, 1989, 36 (04) : 690 - 695
  • [10] CONTROL OF PREDIALYTIC HYPERPHOSPHATEMIA BY ORAL CALCIUM ACETATE AND CALCIUM-CARBONATE - COMPARABLE EFFICACY FOR HALF THE DOSE OF ELEMENTAL CALCIUM GIVEN AS ACETATE WITHOUT LOWER INCIDENCE OF HYPERCALCEMIA
    MORINIERE, P
    DJERAD, M
    BOUDAILLIEZ, B
    ELESPER, N
    BOITTE, F
    WESTEEL, PF
    COMPAGNON, M
    BRAZIER, M
    ACHARD, JM
    FOURNIER, A
    [J]. NEPHRON, 1992, 60 (01): : 6 - 11